{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03433469","nct_id":"NCT03433469","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03433469. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive 80mg osimertinib orally, once a day (PO QD) on days 1-28. Treatment repeats every 28 days for a minimum of 1 cycle prior to surgery in the absence of disease progression or unacceptable toxicity. Investigators will have the option to give a second cycle of study drug prior to surgery if clinically indicated. Depending on the timing of the final scans, patients may ultimately receive up to two weeks additional therapy with study drug beyond end of cycle 1 (or cycle 2) while awaiting surgery. Patients then undergo surgical resection of their cancer. No treatment with the study drug will be given after surgery.","label":"Treatment (osimertinib)","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2027-09-30","type":"ESTIMATED"},"conditions":["Stage I Non-Small Cell Lung Cancer","Stage IA Non-Small Cell Lung Cancer","Stage IB Non-Small Cell Lung Cancer","Stage II Non-Small Cell Lung Cancer","Stage IIA Non-Small Cell Lung Cancer","Stage IIB Non-Small Cell Lung Cancer","Stage IIIA Non-Small Cell Lung Cancer"],"enrollment":{"count":27,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Osimertinib","otherNames":["AZD-9291","Tagrisso"],"type":"DRUG"},{"name":"Therapeutic Conventional Surgery","otherNames":[],"type":"PROCEDURE"}],"last_update":"2026-03-30","lead_sponsor":"University of California, San Francisco","official_title":"A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-01-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With a Major Pathological Response (MPR)","timeFrame":"Up to 1 year"}],"references":[{"citation":"Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. J Clin Oncol. 2024 Sep 10;42(26):3105-3114. doi: 10.1200/JCO.24.00071. Epub 2024 Jul 19.","pmid":"39028931","type":"DERIVED"}],"start_date":{"date":"2018-07-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery","url":"https://clinicaltrials.gov/study/NCT03433469"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03433469"}